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The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in
construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The
recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous
injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an
YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.
D 2005 Elsevier Inc. All rights reserved.Keywords: Yellow and Lassa Fevers; YFV17D vaccine; Recombinant vaccineYellow Fever (YF) and Lassa Fever (LF) are viral
hemorrhagic fevers (VHFs) endemic for West and Central
Africa. Lassa virus (LASV), a complex of closely related
arenaviruses (Salvato et al., 2005), is transmitted from rats
(Mastomys spp.) to humans by either direct contact or by
mucosal exposure (McCormick and Fisher-Hoch, 2002).
Among causative agents of VHFs, LASV affects the second
largest number of people (after dengue). Based on epidemio-
logical studies in Sierra Leone, Guinea and Nigeria, the ‘‘at
risk’’ seronegative population in these countries may be as high
as 59 million, with an annual incidence of illness of 3 million,
fatalities up to 67 thousand and up to 3 million re-infections
(McCormick and Fisher-Hoch, 2002). The sizeable disease
burden and the possibility that LASV can be used as an agent
of biological warfare make a strong case for vaccine
development (Borio et al., 2002; Fisher-Hoch and McCormick,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.12.001
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E-mail address: lukashev@umbi.umd.edu (I.S. Lukashevich).2004; McCormick and Fisher-Hoch, 2002). Live replication-
competent vaccine candidates based on vaccinia (Fisher-Hoch
and McCormick, 2004), vesicular stomatitis virus (VSV)
(Geisbert et al., 2005) and Mopeia virus (MOPV), a non-
pathogenic relative of LASV (Lukashevich et al., 2005; Peters
et al., 1987), have been proposed as potential vaccine
candidates. However, vector safety concern remains the major
obstacle for further development of these vaccines. In contrast
to LF, a live attenuated YFV17D vaccine was available for
human immunization since 1936. Over the past 70 years, more
than 400 million people were immunized with a remarkable
record of safety and efficacy (Monath, 2004). A single
subcutaneous (s.c.) immunization with YFV17D elicits long-
lasting protective antibody and T cell responses. Based on an
outstanding record in humans, the YFV17D has been recently
used as a vector for the development of vaccines against other
flaviviruses (Japaneses encephalitis, dengue, West Nile virus)
and against unrelated pathogens (Plasmodium yoelii, influenza
M-protein, oncogenes) (Barba-Spaeth et al., 2005; Bonaldo et
al., 2005; Monath, 2004; Tao et al., 2005). Here, we describe a6) 299 – 304
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and capable of replicating in vivo and protecting guinea pigs
against LASV challenge.
Results and discussion
Recently, a stable full-length infectious YFV17D cDNA has
been constructed (Bredenbeek et al., 2003). In the present
study, we have used this cDNA to construct a YFV17D
recombinant that expresses the LASV GPC protein. This
protein is the LASV glycoprotein precursor that is cleaved by
subtilase SKI-1/S1P into structural GP1 and GP2 glycoproteins
(Lenz et al., 2000). A cDNA fragment encompassing the
complete sequences encoding LASV GP1 and GP2, but
lacking the 58 amino acids of the GPC signal sequence, was
fused in frame between the YFV E and NS1 genes (Fig. 1). The
construct was designed so that LASV GPC protein would be
released from the YFV17D polyprotein by host signalase. In
this construct, the COOH-terminal 23 hydrophobic amino acids
of the YFV17D E gene were duplicated downstream of the
LASV GPC gene to serve as a signal sequence to ensure
insertion of the YFV NS1 protein into the endoplasmic
reticulum (ER). In vitro-made RNA from the recombinant
clone and from the parental YFV17D clone was transfected
into BHK-21J cells by electroporation and labeled with 3H-
uridine in the presence of actinomycin D. As seen in Fig. 1D, a
single RNA was detected in the labeled cells that were
transfected with the recombinant YFV17D/LASV-GPC. ThisFig. 1. Schematic representation of YFV17D/LAS-GPC construct. (A) LASV pre-G
GPC construct. SS, signal sequence; TMD, trans-membrane domain: GP1 and GP2 a
(D) detection of chimeric YF/LAS RNA in cells transfected with recombinant RNA
electroporation. YFV17D, RNA from cells electroporated with the parental YFV17D
GPC RNA; Mock, RNA from mock transfected cells.RNA migrated more slowly than YFV17D RNA and was not
detectable in mock transfected cells.
The recombinant virus replicated in BHK-21 and Vero cells
to titers of over 106 PFU/ml and produced plaques that were
slightly smaller than those produced by the parental virus,
YFV17D (data not shown). To demonstrate the expression of
the LASV GPC in cells transfected with YFV17D/LASV-GPC
RNA, cells were analyzed by indirect immunofluorescense.
Both the wild-type YFV17D and the YFV17D/LASV-GPC
transfected cells were positively stained with anti-YFV17D
NS1 antibodies showing a perinuclear punctate pattern that is
typical for YFV NS1 expression (Fig. 2A). However, only cells
transfected with the recombinant YFV17D/LAS-GPC RNA
were positively stained with LASV GP1-monoclonal anti-
bodies. The results of the metabolic RNA labeling and
immunofluorescense studies demonstrate that the YFV17D/
LASV-GPC is replication-competent in cell cultures. The
expression of LASV GPC was detected in infected Vero cells
after at least 5 passages of the recombinant virus, suggesting
that the virus is reasonably stable.
Western blot analysis was performed to determine whether
the LASV GPC protein was properly released from the
recombinant YFV17D/LASV protein precursor. As shown in
Fig. 2B, monoclonal antibodies directed against LASV GP1
or polyclonal antibodies to LASV GP2 detected both GPC
and GP1 or GP2 glycoproteins, respectively, in lysates of
cells transfected with YF17D/LASV-GPC RNA but not with
the parental YFV17D RNA. In addition to GPC and GP1/PC protein; (B) YFV17D genome organization; (C) chimeric YFV17D/LAS-
re final products of Lassa GPC processing which form the mature virion spikes;
and labeled with 3H-uridine in the presence of actinomycin D, 18–24 h after
RNA; YF/LF, RNA from cells electroporated with recombinant YFV17D/LAS-
Fig. 2. Expression of LASV glycoproteins in transfected cells. (A) Immunofluorescense staining of YFV NS1 (A1, A2) and LASV GPC (A3, A4) in cells transfected
with YFV17D RNA (A1, A3) or YFV17D/LASV-GPC (A2, A4). (B) Western blot analysis of LASV GPC processing in BHK-21 cells. At 24 h after transfection,
cells were collected, subjected to SDS-PAGE and proteins were transferred to blots. The blots were probed with LASV GP1- or GP2-specific antibodies. Molecular
weight markers in kDa are indicated. Position of the unglycosylated form of GPC is indicated by asterisk.
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stained with anti-GP1 monoclonal antibodies in transfected
cells. This protein seems to be an unglycosylated form of
LASV GPC that is not translocated to the ER (Lenz et al.,
2000). These results demonstrate that GPC is properly
released from the YFV17D/LASV polyprotein and subse-
quently cleaved into GP1 and GP2. However, the substantial
part of LASV glycoproteins expressed in transfected cells
remained unprocessed.
The wild-type YFV infection is primarily viscerotropic in
humans and non-human primates. The attenuated YFV17D is
not viscerotropic and replicates poorly in tissues of experi-
mental animals (guinea pigs, hamsters, non-human primates).
In humans, non-viscerotropism is associated with attenuation
and viremia occurred principally between days 4 and 6 and
does not exceed 2 logs10 PFU/ml (Monath, 2004). LASV
infection of guinea pigs and non-human primates is associated
with high viremia and the virus replicates very well in target
tissues making these animals useful models for human LF
(Peters et al., 1987). In LF patients, high viremia (>1  103
TCID50/ml) was associated with high fatality rate and high
viremia together with high levels of liver enzymes in plasma
(AST > 150 IU/L) carried a risk of death in 78% of LF cases
(McCormick and Fisher-Hoch, 2002).
The main goal of the first set of animal experiments was to
evaluate the YFV17D/LASV-GPC replication competence and
immunogenicity in vivo. The Hartley guinea pigs were
inoculated s.c. with 1  105 PFU of YFV17D/LAS-GPC and
on day 14 all animals were boosted with the same dose of the
recombinant virus. Blood and tissue samples were collected
from vaccinated animals at different time points for hematol-
ogy, blood chemistry, RNA extraction, plaque assay, virus
isolation and ELISA. As expected, the inoculated animals had
no clinical manifestations and all standard measurable blood
and chemistry parameters were in normal ranges. In plasma,
the recombinant virus was not detectable by plaque assay or by
biological amplification (cocultivation in Vero cells). Recom-binant viral RNA was not detectable by RT/PCR in 140 Al of
plasma extracted on days 4, 10, and 21. However, when RNA
samples were prepared from 0.5 ml of total blood, an RT/PCR
assay gave a strong positive signal on day 4 after YFV17D/
LAS-GPC inoculation (Fig. 3A). Still, blood samples collected
on day 10 and 21 were PCR negative (not shown). Viral RNA
sequences were only transiently detectable on days 7–14 in
spleen and liver (Fig. 3A). Nucleotide sequence analysis of
PCR products confirmed their derivation from YFV17D/LAS-
GPC. Taken together, these data confirm that recombinant
YF17D/LAS-GPC replicated poorly in tissues (blood and the
viscera, particularly liver and spleen) of vaccinated guinea pigs.
Interestingly, in clinical trials in individuals vaccinated with
chimeric YFV17D-based vaccines, viremia levels were even
lower than the levels of YFV17D determined to be safe
(Monath, 2004). This suggests that insertion of a foreign gene
can affect in vivo viral replication and make recombinant
YFV17D-based vaccines even safer than the parental vaccine,
YFV17D.
Plasma samples collected from vaccinated Hartley guinea
pigs were analyzed for the presence of antibodies against
YFV17D and LASVantigens prepared as described in Materials
and methods. Samples collected during the first 2 weeks after
immunization were negative in IgG ELISA (<1:100). After a
boost immunization, specific antibodies were detected to both
viral antigens, LASV and YFV17D (Fig. 3). These results
indicate that, in spite of low level of replication in tissues, the
YFV17D/LAS-GPC recombinant virus was able to elicit
specific immune responses against the vector, YFV17D, and
LASV-GPC. As expected, vaccination of animals with YFV17D
(‘‘empty vector’’ control) did not elicit antibodies against LASV
(not shown). Immunogenicity of the recombinant YFV17D/
LAS-GPC seems to be lower than the immunogenicity of the
another vaccine candidate, attenuated MOP/LAS reassortant,
clone ML29 (Lukashevich et al., 2005). This reassortant
induced specific IgG ELISA responses detectable on day 14
after a single immunization (1:5000 end-point dilution).
Fig. 3. Replication of YFV17D/LASV-GPC in Hartley guinea pigs. (A) Detection of YFV17D/LASV-GPC sequences in tissues: 1, Positive PCR control
(recombinant cDNA); 2, negative PCR control; 3, DNA ladder, 200 and 100 nt; 4, total blood, 4 days after vaccination; 5–8, liver, 4, 7, 10, and 14 days, respectively;
9–12, spleen, 4, 7, 10, and 14 days, respectively. (B, C) Detection of anti-YFV17D and anti-LASVantibodies in plasma of vaccinated animals. LASVand YFV17D
antigens were prepared as described in Materials and methods and used in IgG ELISA with plasma samples of 6 guinea pigs. Samples from two animals were
collected at indicated time points and used in dilution 1:100. Polyclonal anti-YFV17D mouse antibodies and anti-LASV human serum were used as a positive control
in dilution 1:1000.
Fig. 4. Challenge experiments in strain 13 guinea pigs. Animals were
vaccinated with one subcutaneous injection of MOP/LAS (103 PFU) or with
YFV17D/LASV-GPC recombinant (105 PFU) and challenged subcutaneously
with LASV (Josiah), 103 PFU per animal. Death or survival past 21 days was
set up as an endpoint (Lukashevich et al., 2005; Peters et al., 1987).
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to LASV and the infection kills no more than 30% of the
animals at doses as high as 2  105 PFU/animal (Peters et al.,
1987). In contrast, strain 13 guinea pigs are extremely
sensitive to the virus and the LD50 for Josiah strain is 0.3
PFU (Lukashevich et al., 2005; Peters et al., 1987; Pushko et
al., 2001). In the second set of animal experiments, strain 13
guinea pigs were used to evaluate protective efficacy of the
recombinant YFV17D/LAS-GPC vaccine. The ideal vaccine
for LF should be capable of inducing cell-mediated protection
against LASV strains after a single-shot application (Fisher-
Hoch and McCormick, 2004). Five strain 13 guinea pigs were
s.c. vaccinated with 1  105 PFU of YFV17D/LASV-GPC
and challenged on day 21 with 1000 PFU of LASV (Josiah).
The control group included 5 animals injected with saline
(negative control) and challenged with the same dose of
LASV. As a positive vaccination control, a reassortant MOP/
LAS virus (Lukashevich et al., 2005) was included in these
experiments. As seen in Fig. 4, all MOP/LAS-vaccinated
guinea pigs survived after LASV challenge and all animals
died in the saline-vaccinated group. Four YFV17D/LAS-GPC-
vaccinated animals survived after challenge. In this group, one
animal died at day 14 after challenge and LASV infection was
confirmed by biological and RT/PCR amplification of LASV
RNA (not shown).
The YFV17D-based vaccines expressing foreign CTL
epitopes (Bonaldo et al., 2005; McAllister et al., 2000; Tao
et al., 2005) replicate poorly in animal tissues, and the
mechanism of induction of protective T cell responses is not
clearly understood. Preferential replication of recombinant
viruses in dendritic cells (DCs) at the site of inoculation was
proposed to explain the strong immunogenicity of YFV17D-based viruses (Tao et al., 2005). Indeed, it has been shown that
DCs infected with YFV17D or YFV17D carrying recombinant
epitopes are resistant to cytopathogenicity and effectively
process and present antigens to stimulated CD8+T cell
(Barba-Spaeth et al., 2005). Stable association of viral epitopes
with DCs offers a mechanism for the robust and long-lasting
immunity associated with YFV17D-based vaccination.
In our experiments, YFV17D/LAS-GPC vaccination eli-
cited humoral immune responses against YFV17D and LASV
antigens. Neutralizing antibodies play the major role in
protection against YF (Monath, 2004). In contrast, protection
against LASV is associated with strong cellular immune
responses in the absence of measurable neutralizing antibodies
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Hoch, 2002). In YFV17D/LAS-GPC-vaccinated group, 80% of
animals were protected against the fatal challenge. In a positive
control group (MOP/LAS), all vaccinated animals were
protected against LASV challenge (Fig. 4). Incomplete
protection could be explained by differences in vaccine
formulation (GPC + NP vs. GPC) and by GPC sequence
differences between AV and Josiah strains of LASV (Gunther
et al., 2000). The MOP/LAS reassortant contains the LASV
nucleocapsid (NP) sequence and the GPC of LASV (Josiah)
(Lukashevich et al., 2005). A solid body of literature indicates
that both major LASV antigens, GPs and NP, are important for
induction of long lasting cross-reactive cell-mediated immunity
(Fisher-Hoch and McCormick, 2004; Oldstone et al., 2001;
Pushko et al., 2001; Rodriguez-Carreno et al., 2005; ter Meulen
et al., 2000). We are considering several approaches to making
YFV17D-based constructs expressing LASV NP to enhance
the protective potential of recombinant the YFV17D/LASV-
GPC vaccine.
Proper processing and presentation of LASV GPC in the
YFV17D vector is another issue that has to be analyzed in
more detail. Only a fraction of LASV GPC was processed
into GP1 and GP2 in the YFV17D/LASV-GPC transfected
cells (Fig. 2). The LASV GPC signal peptide is cotransla-
tionally released when GPC is directed to the ER. It has been
shown that substitution of the GPC signal peptide with an
unrelated signal sequence does not affect translocation of
GPC into the ER (Eichler et al., 2003). The cleavage of GPC
into GP1 and GP2 is a rather late event in LASV glycoprotein
maturation. Since the GPC signal peptide promotes LASV
GPC processing by functioning as a trans-acting factor
mediating GPC cleavage (Eichler et al., 2003), the deletion
of the GPC signal sequence is the most likely reason for
inefficient cleavage of GPC into GP1 and GP2 in cells
infected with the recombinant YFV17D/LAS-GPC virus. Our
initial attempts to insert the whole pre-GPC LASV sequence
resulted in low titers of recombinant virus and in low levels
of LASV GPC expression. It seems that one or two
hydrophobic domains of the LASV pre-GPC signal peptide
were interfering with the proteolytic processing of the
YFV17D polyprotein.
The YFV17D backbone has been used for the development
of recombinant vaccines against several flavivirus-mediated
diseases like Japanese encephalitis, dengue types 1–4 and
West Nile viruses (Monath, 2004). These vaccines elicited
protective neutralizing antibodies in rodent and monkey
models, passed safety tests and are currently in human trials.
Recently, the YFV17D vector was successfully used to design
recombinant vaccines for delivery of CTL epitopes against P.
yoelii, a rodent malaria parasite (Bonaldo et al., 2005; Tao et
al., 2005), the immunodominant HLA-A2 M1 epitope of
influenza M protein (Barba-Spaeth et al., 2005) and as an
attractive therapeutic anticancer vaccine (McAllister et al.,
2000). These previous successes and the data presented in this
study demonstrate that YFV17D may be a very suitable vector
to develop a safe and effective bivalent YF/LF vaccine for
Africa.Materials and methods
The YFV17D/LASV-GPC plasmid was constructed in the
background of the full-length YFV17D cDNA clone (Breden-
beek et al., 2003) by fusion PCR mutagenesis. The LASV-GPC
gene of the AV strain (Gunther et al., 2000) was amplified by
RT/PCR and cloned into pcDNA. The nucleotide sequences of
PCR-derived DNA fragments and gene fusions were confirmed
by sequencing. The recombinant YFV17D/LASV-GPC plas-
mid was linearized by XhoI and used for in vitro RNA
transcription. In vitro RNA transcription, electroporation of the
BHK-21J cells, in vivo RNA labeling, preparation of virus
stocks, immunofluorescense and plaque assays were previously
described (Bredenbeek et al., 2003). For Western blot analysis,
transfected cells were lysed at 24 h post-electroporation, lysates
were subjected to SDS-PAGE separation and proteins were
electroblotted to PDVF membranes (Hybond-P, Amersham,
Piscataway, NJ). Monoclonal anti-GP1 and polyclonal rabbit
anti-GP2 antibodies (gift from W. Garten, the Institut fu¨r
Virologie der Phillips-Universita¨t Marburg, Germany) were
used to identify the LASV glycoproteins after incubation with
an appropriate secondary goat IgG conjugated to alkaline
phosphatase using NBT/BCIP (Invitrogen, Carlsbad, CA) as
chromogenic substrate.
Sixteen outbred guinea pigs were subcutaneously inoculated
with 1  105 PFU/0.5 ml of the recombinant YFV17D/LASV-
GPC virus and two animals were sacrificed at days 0, 4, 7, 10
and 14 to track the virus distribution in blood and tissues. RNA
from plasma and tissue samples was extracted using QIAamp
viral minispin and RNeasy kits, respectively (Qiagen Inc.,
Valencia, CA). RNA from total blood was extracted using a
RiboPure isolation kit (Ambion, Inc., Austin, TX). Isolated
RNA samples were converted into cDNA (SuperScript III,
Invitrogen) and amplified with YFV17D primers (sense: 5V-
AATCGAGTTGCTAGGCAATAAACAC; anti-sense: 5V-
TCCCTGAGCTTTACGACC AGA). At day 14, six animals
were boosted with the same dose of the recombinant virus and
plasma samples were collected on days 8, 15 and 24 after to
measure antibody responses against YFV17D and LASV-GPC
in IgG ELISA. Antigens were prepared from serum-free virus
stocks of YFV17D and MOP/LAS (Lukashevich et al., 2005)
by ultracentrifugation on sucrose cushion. Concentrated viruses
were suspended in carbonate–bicarbonate buffer, briefly
sonicated and used to cover wells of microtitration plates
(overnight, 4 -C). After blocking, 1:100 dilutions of guinea pig
sera were added and incubated for 2 h at room temperature.
Peroxidase-labeled goat anti-guinea pig IgG (KPL, Gaithers-
burg, MD) and substrate solution (Turbo TMB-ELISA, Pierce,
Rockford, IL) were used for color development. Challenge
experiments were performed in strain 13 guinea pigs purchased
from USAMRIID (Fort Detrick, Frederick, MD). Vaccinated
animals were challenged within a biosafety level 4 facility at
the Southwest Foundation for Biomedical Research (San
Antonio, TX) as previously described (Lukashevich et al.,
2005). The challenge stock of LASV (Josiah) was obtained
from the Centers for Disease Control and Prevention (Atlanta,
GA).
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